ZEALAND PHARMA AS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 81
- Registration Number
- NCT02660008
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT02390141
- Locations
- 🇩🇪
Profil GmbH, Neuss, Germany
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 111
- Registration Number
- NCT02367053
- Locations
- 🇩🇪
Profil GmbH, Neuss, Germany
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 591
- Registration Number
- NCT01977755
- Locations
- 🇩🇰
The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 66
- Registration Number
- NCT00868660
- Locations
- 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
Phase 2
Terminated
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00283361
- Locations
- 🇺🇸
LAC-USC Medical Center-Division of Cardiology, Los Angeles, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Health First Clinical Research Institute, Melbourne, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath